Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual RetailInvestorConferences.com
VANCOUVER, British Columbia and MENLO PARK, Calif., June 2, 2014 /CNW/ - DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"), a clinical-stage company advancing breakthrough cancer therapeutics and located in Vancouver, British Columbia and Menlo Park, Calif., today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com on June 5th.
DATE: Thursday, June 5, 2014
TIME: 11:30 AM EDT
LINK: http://retailinvestorconferences.com > red "register/ watch event now" button
This will be a live, interactive online event where the company will provide further insight to its recent announcement of clinical data at the 50th Annual Meeting of the American Society of Clinical Oncology and strategies for advancement of VAL-083 toward registration-directed clinical trials and continued creation of shareholder value. Investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
Recent DelMar Pharma Clinical Highlights
The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The primary endpoint of this stage of DelMar's current study is to determine a modernized dosing regimen for advancement to registration-directed clinical trials. DelMar recently completed the sixth cohort (30mg/m2) and have opened the seventh cohort (40mg/m2) in our GBM clinical trial. Our interim results show:
In summary, DelMar reported that:
- To date, one of two GBM patients in cohort 6 (30 mg/m2) exhibited stable disease after 1 cycle of treatment. Outcomes analysis of cohorts 6 and 7 are ongoing.
- No drug-related serious adverse events have been detected, and maximum tolerated dose (MTD) has not been reached at doses up to 30 mg/m2. Enrollment and evaluation of Cohort 7 (40mg/m2) is ongoing.
- Pharmacokinetics are linear and consistent with previous published data suggesting that concentrations of VAL-083 being obtained are effective against glioma cell lines in vitro.
In earlier cohorts, DelMar reported that two patients exhibited a response (stable disease or partial response) with a maximum response of 28 cycles (84 weeks) and improved clinical signs prior to discontinuing due to adverse events unrelated to study.
DelMar has also presented data demonstrating that the cytotoxic activity of VAL-083 is independent of MGMT, the enzyme believed to cause resistance to the current front-line therapy in the treatment of GBM.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals (OTCQB: DMPI) was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
For more information, please visit http://www.delmarpharma.com or follow us on Twitter @DelMarPharma or Facebook.com/DelMarPharma.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
SOURCE: DelMar Pharmaceuticals, Inc.
For further information:
DelMar Contacts: Jeffrey A. Bacha, President & CEO, (604) 629-5989, Booke & Company Investor Relations, firstname.lastname@example.org; RetailInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, email@example.com